Prospective observational study on efficacy and safety of PEGASYS for the treatment of patients with HBeAg positive or HBeAg negative chronic active hepatitis B
Latest Information Update: 20 Sep 2019
Price :
$35 *
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Biomarker; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 19 Sep 2019 Status changed from active, no longer recruiting to completed.
- 28 May 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 01 Jun 2012 New trial record